SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging as the community reacts to positive Phase 3 trial data for a personalized mRNA melanoma vaccine, sparking an aggressive short squeeze. While retail investors are debating the long-term potential of the cancer treatment pipeline, many are actively monitoring the stock for further volatility and potential share offerings.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is surging following a record-breaking fiscal quarter that saw substantial growth in trading volumes and customer assets, alongside a successful transition following the elimination of pattern day trader rules. The community is buzzing with debate over potential upside as investors discuss everything from short squeezes and bullish price targets to historical volatility surrounding earnings reports.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors draw parallels between its WT1-targeting immunotherapy platform and the success of recently reported cancer vaccine data, driving anticipation for an imminent Phase 3 trial result. The community is actively discussing the stock's potential for a significant re-rating, fueled by a heavily shorted float and high call option volume as investors position for a major clinical milestone.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as institutional ownership rises to approximately 90%, fueling community speculation that the company is being positioned for a strategic acquisition or major partnership deal. Investors are closely monitoring the potential for a breakthrough with the Matrix-M adjuvant technology and upcoming catalysts related to the Sanofi-led combination vaccine.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) is trending as gold prices rally and institutional interest grows, with investors positioning for potential rate cuts and hedging against fiscal concerns. The community is actively discussing gold's role as a store of value amid significant national debt levels, while traders monitor technical breakouts and volatility in miners' momentum.

ETF Opportunities Trust - T-REX 2X Long SNDK Daily Target ETF

SNDU is trending as community members actively discuss strategies for navigating the leveraged ETF's price swings, often drawing parallels between their positions and the underlying volatility of SanDisk (SNDK). Investors are focused on timing entry points during pullbacks and coordinating sell orders to influence price action, while debating the potential impacts of sector-wide news and future analyst projections.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as investors aggressively debate the long-term impact of its recent security audit and infrastructure upgrades, with a divided community weighing the risks of potential supply vulnerabilities against the potential for a privacy-focused rebound. Active discussions are heavily focused on technical chart patterns and the coin's ability to maintain its relative strength while market participants weigh the merits of privacy technology against wider cryptocurrency market volatility.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently trending as investors debate the potential for institutional accumulation and a pending buyout amid the recent FDA approval of its IgA nephropathy drug, Trutakna. While some community members remain frustrated by the stock's recent price stagnation compared to the broader biotech sector, others view the current consolidation as a strategic entry point for long-term institutional positioning.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is rallying as investors react to increased bond buyback activity and recent high-level meetings between crypto executives and government officials. The price surge has triggered a massive wave of short liquidations, fueling community excitement as bulls target key technical breakout levels while debating whether this move signals the definitive end of the current bear cycle.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is experiencing significant volatility and trend interest driven by sector-wide rotation and investor focus on high-conviction clinical catalysts, despite broad market headwinds. Community members are actively debating the mechanics of algorithmic basket buying versus fundamental laggards, while keeping a close eye on upcoming Phase 3 trial readouts and potential M&A activity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Industrial Products Stocks Lagging  Lincoln Electric (LECO) This Year?

Here is how Lincoln Electric Holdings (LECO) and UniFirst (UNF) have performed compared to their sector so far this year.

Here's Why Lincoln Electric Holdings (LECO) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

MATTHEWS INTERNATIONAL CORPORATION ANNOUNCES THE APPOINTMENT OF MICHAEL J. WHITEHEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

MATTHEWS INTERNATIONAL CORPORATION ANNOUNCES THE APPOINTMENT OF MICHAEL J. WHITEHEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER MATTHEWS INTERNATIONAL CORPORATION ANNOUNCES THE APPOINTMENT OF MICHAEL J. WHITEHEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER PR Newswire PITTSBURGH, Aug. 11, 2026...

CNM or LECO: Which Is the Better Value Stock Right Now?

CNM vs. LECO: Which Stock Is the Better Value Option?

Snap-on Climbs 10.5% in 3 Months as Growth Faces New Valuation Risks

SNA's 10.5% three-month climb is backed by sales and margin gains, but a near-peak valuation raises the stakes for continued execution

Is Snap-on Stock a Buy as Strong Margins Meet a Premium Valuation?

SNA's strong margins, cash flow and growth avenues face a key test as its premium valuation and mixed segment trends shape the stock outlook.

LECO Q2 Earnings Beat on Organic Sales Growth, Stock Jumps 8%

Lincoln Electric shares jump 8% after Q2 earnings beat estimates, sales rose 12% and 2026 sales growth guidance increased.

Here's Why Lincoln Electric Holdings (LECO) is a Strong Growth Stock

Is Lincoln Electric (LECO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Lincoln Electric (LECO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Lincoln Electric (LECO) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Lincoln Electric (LECO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Lincoln Electric Holdings, Inc. engages in the manufacture of arc welding equipment, consumable welding products, and other welding and cutting products. It operates through the following segments: Americas Welding, International Welding, and The Harris Products Group. The Americas Welding segment includes welding operations in North and South America. The International Welding segment primarily deals with welding operations in Europe, Africa, Asia, and Australia. The Harris Products Group segment refers to the company's global cutting, soldering, and brazing businesses as well as the retail business in the United States. The company was founded by John C. Lincoln and James F. Lincoln on December 5, 1895 and is headquartered in Cleveland, OH.

Lincoln Electric Holdings, Inc.

Lincoln Electric Stock Gains After Q4 Earnings Beat: Retail Stays Extremely Bullish

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$2.82	--	--	N/A
Q2 '26	$2.81	$2.93	4.31%	BEAT
Q1 '26	$2.44	$2.50	2.47%	BEAT
Q4 '25	$2.54	$2.65	4.22%	BEAT
Q3 '25	$2.42	$2.47	1.91%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings